New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - flecainide acetate 100.008mg;   - modified release capsule - 100 mg - active: flecainide acetate 100.008mg   excipient: capsugel black 01.911 capsugel grey op.c006 capsugel white op colloidal silicon dioxide crospovidone macrogol 400 magnesium stearate methacrylic acid copolymer microcrystalline cellulose povidone purified talc - in patients without structural heart disease and without myocardial infarction, flecainide controlled release capsules are indicated for the prevention of: 1. supraventricular arrhythmias · paroxysmal supraventricular tachycardias (psvt) including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms; · paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. 2. ventricular arrhythmias · documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia (vt) if they are considered life-threatening in the judgement of the attending physician. not indicated for less severe ventricular arrhythmias even if symptomatic.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - flecainide acetate 200.016mg;   - modified release capsule - 200 mg - active: flecainide acetate 200.016mg   excipient: capsugel black 01.911 capsugel flesh op.c012 capsugel grey op.c006 colloidal silicon dioxide crospovidone macrogol 400 magnesium stearate methacrylic acid copolymer microcrystalline cellulose povidone purified talc - in patients without structural heart disease and without myocardial infarction, flecainide controlled release capsules are indicated for the prevention of: 1. supraventricular arrhythmias · paroxysmal supraventricular tachycardias (psvt) including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms; · paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. 2. ventricular arrhythmias · documented life-threatening ventricular arrhythmias such as sustained ventricular tachycardia (vt) if they are considered life-threatening in the judgement of the attending physician. not indicated for less severe ventricular arrhythmias even if symptomatic.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - flecainide acetate - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

milpharm ltd - flecainide acetate - oral tablet - 100mg

Malta - English - Medicines Authority

actavis uk limited whiddon valley, barnstaple, n. devon, ex32 8ns, united kingdom - flecainide acetate - tablet - flecainide acetate 100 mg - cardiac therapy

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - flecainide acetate - tablet - flecainide acetate 100 milligram(s) - cardiac therapy

Malta - English - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - flecainide acetate - tablet - flecainide acetate 100 mg - cardiac therapy

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - flecainide acetate, quantity: 100 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; hydrogenated vegetable oil; magnesium stearate; croscarmellose sodium; pregelatinised maize starch - supraventricular arrhythmias: (a) due to pre-excitation syndromes, eg wolff-parkinson-white and lown-ganong-levine syndromes. (b) due to dual av nodal pathways in patients with debilitating symptoms. (c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. although tambocor may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, tambocor should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate. use of tambocor in chronic atrial fibrillation has not been adequately studied and is not recommended. 2. life threatening ventricular arrhythmias not controlled by other drugs. intravenous tambocor is indicated when rapid control or short-term prophylaxis of the above arrhythmias is the main clinical requir

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - flecainide acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; hydrogenated vegetable oil; magnesium stearate; pregelatinised maize starch - supraventricular arrhythmias: (a) due to pre-excitation syndromes, eg wolff-parkinson-white and lown-ganong-levine syndromes. (b) due to dual av nodal pathways in patients with debilitating symptoms. (c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms. although tambocor may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, tambocor should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate. use of tambocor in chronic atrial fibrillation has not been adequately studied and is not recommended. 2. life threatening ventricular arrhythmias not controlled by other drugs. intravenous tambocor is indicated when rapid control or short-term prophylaxis of the above arrhythmias is the main clinical requir

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - flecainide acetate, quantity: 50 mg - tablet - excipient ingredients: magnesium stearate; croscarmellose sodium; maize starch; silicified microcrystalline cellulose - flecain is indicated for:,1. supraventricular arrhythmias:,a) due to pre-excitation syndromes, e.g. wolff-parkinson-white and lown-ganong-levine syndromes,b) due to dual av nodal pathways in patients with debilitating symptoms,c) paroxysmal atrial fibrillation/flutter (paf) associated with disabling symptoms,although flecainide acetate may be effective in supraventricular arrhythmias in patients with structural heart disease, its use has been associated with life-threatening and occasionally fatal ventricular arrhythmias. in these patients, particularly in the presence of impaired left ventricular function, flecain should be used with extreme caution, preferably after other antiarrhythmic drugs have been tried or considered inappropriate.,use of flecainide acetate in chronic atrial fibrillation has not been adequately studied and is not recommended.,2. life threatening ventricular arrhythmias not controlled by other drugs.,flecain tablets are used for continuous maintenance of normal rhythm following initial oral or intravenous therapy or conversion by other means.,prescribers should also consult the "precautions" section of this product information.